Compare SHBI & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHBI | LBRX |
|---|---|---|
| Founded | 1876 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 636.2M | 602.6M |
| IPO Year | 1997 | N/A |
| Metric | SHBI | LBRX |
|---|---|---|
| Price | $19.19 | $30.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $19.17 | ★ $46.60 |
| AVG Volume (30 Days) | 228.2K | ★ 299.4K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | ★ 34.85 | N/A |
| EPS | ★ 1.78 | N/A |
| Revenue | ★ $20,853,000.00 | N/A |
| Revenue This Year | $8.97 | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | $10.97 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.67 | $13.40 |
| 52 Week High | $20.68 | $33.47 |
| Indicator | SHBI | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 60.06 |
| Support Level | $18.88 | $21.90 |
| Resistance Level | $19.31 | N/A |
| Average True Range (ATR) | 0.50 | 2.05 |
| MACD | -0.04 | 0.15 |
| Stochastic Oscillator | 21.00 | 67.10 |
Shore Bancshares Inc is a financial holding company based in the United States. Through its subsidiaries, it provides consumer and commercial banking products and services, as well as secondary mortgage lending, trust, wealth management, and financial planning services. The group caters to both business and individual clients, offering checking, savings, certificates of deposit, and overnight investment sweep accounts; commercial lending services, including secured and unsecured loans, working capital loans, lines of credit, etc; and safe deposit boxes, debit cards, telephone banking, and other financial products and services.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.